V-set domain-containing T-cell activation inhibitor 1 is a protein that in humans is encoded by the VTCN1 gene. [5][6][7] B7H4 belongs to the B7 family (see CD80; MIM 112203) of costimulatory proteins.

2024年12月25日 · VTCN1 (V-Set Domain Containing T Cell Activation Inhibitor 1) is a Protein Coding gene. Diseases associated with VTCN1 include Renal Cell Carcinoma and Pancreatic Cancer. Among its related pathways are T cell modulation in …

2025年1月4日 · Aryl Hydrocarbon Receptor Directly Regulates VTCN1 Gene Expression in MCF-7 Cells. B7-H4 expression promotes non-small cell lung cancer progression via AMPK/mTOR signaling. Elevated expression of B7 homolog 4 is associated with disease progression in upper urinary tract urothelial carcinoma.

VTCN1, a T‐cell regulator, belongs to the immunoglobulin superfamily. It is more highly expressed in tumor tissues than in normal tissues, which suggests that it could serve as a tumor‐related agent. We hypothesize the gene variants for this ...

2022年11月1日 · VTCN1 is a known negative regulator of T cell response which makes it an astonishing target to be explored in SLE. For the first time, Ramos et al. reported that the VTCN1 gene region showed the strongest novel association with SLE (Ramos et al., 2011). In 2017, Xiao et al. developed a murine model of SLE and demonstrated that VTCN1 KO-mice ...

Recent studies implicated a B7-like negative costimulatory protein, V-set domain-containing T-cell activation inhibitor-1 (VTCN1), as a molecule capable of inhibiting T-cell activation and, potentially, an important constituent in experimental models of T1D.

2024年4月3日 · Altered Levels of Negative Costimulatory Molecule V-Set Domain-Containing T-Cell Activation Inhibitor-1 (VTCN1) and Metalloprotease Nardilysin (NRD1) are Associated with Generalized Active Vitiligo.

2022年11月1日 · Targeting autoimmune diseases via immunomodulation has become an essential strategy in today's era. Dysregulation of VTCN1 (V-set domain containing T cell activation inhibitor 1) has resulted in the exacerbation of various autoimmune diseases.

2024年1月4日 · Clinical resource with information about VTCN1, Identification of a novel susceptibility locus for juvenile idiopathic arthritis by genome-wide association analysis., and available tests. There are links to practice guidelines and authoritative resources like GeneReviews, PubMed, MedlinePlus, PharmGKB and clinicaltrials.gov.

Highly glycosylated sialomucin; expressed on immune cells. Negatively regulates T-cell-mediated immune response by inhibiting T-cell activation, proliferation, cytokine production and development of cytotoxicity.